EP1006183A1
(de)
*
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rekombinante, lösliche Fc-Rezeptoren
|
EP1201681A1
(de)
*
|
2000-10-30 |
2002-05-02 |
Millennium Pharmaceuticals, Inc. |
"Fail" Moleküle und deren Verwendung
|
GB0127206D0
(en)
*
|
2001-11-13 |
2002-01-02 |
Univ Liverpool |
Treatment of inflammatory conditions
|
DE10157290A1
(de)
*
|
2001-11-22 |
2003-06-05 |
Max Planck Gesellschaft |
Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
ATE536188T1
(de)
|
2002-08-14 |
2011-12-15 |
Macrogenics Inc |
Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US7355008B2
(en)
|
2003-01-09 |
2008-04-08 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US7960512B2
(en)
|
2003-01-09 |
2011-06-14 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
EP2052713A3
(de)
|
2003-01-13 |
2009-05-20 |
Macrogenics, Inc. |
Lösliche FcgammaR-Fusionsproteine und Verfahren zu deren Verwendung
|
WO2004081197A2
(en)
*
|
2003-03-12 |
2004-09-23 |
Incyte Corporation |
Immune response associated proteins
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
CA2545603A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
|
US8853363B2
(en)
|
2003-11-26 |
2014-10-07 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Substance binding human IgG Fc receptor IIb (FcγRIIb)
|
EP1761563A4
(de)
|
2004-05-10 |
2008-05-14 |
Macrogenics Inc |
HUMANISIERTE FC gamma SPEZIFISCHE ANTIKÖRPER UND VERFAHREN ZU DEREN ANWENDUNG
|
CA2587766A1
(en)
|
2004-11-10 |
2007-03-01 |
Macrogenics, Inc. |
Engineering fc antibody regions to confer effector function
|
EP2573114B1
(de)
|
2005-08-10 |
2016-03-30 |
MacroGenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden Fc-Regionen und Anwendungsverfahren dafür
|
WO2008105886A2
(en)
|
2006-05-26 |
2008-09-04 |
Macrogenics, Inc. |
HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
WO2008019199A2
(en)
|
2006-06-26 |
2008-02-14 |
Macrogenics, Inc. |
FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
|
CA2656224C
(en)
|
2006-06-26 |
2018-01-09 |
Macrogenics, Inc. |
Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
|
US8652466B2
(en)
|
2006-12-08 |
2014-02-18 |
Macrogenics, Inc. |
Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
|
AU2008209436A1
(en)
*
|
2007-01-23 |
2008-07-31 |
Zymogenetics, Inc. |
Soluble Fc gamma R1a for reducing inflammation
|
JP5484041B2
(ja)
*
|
2007-02-23 |
2014-05-07 |
学校法人関西学院 |
蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
|
EP2247304B1
(de)
|
2008-04-02 |
2016-05-25 |
MacroGenics, Inc. |
Her2/neu-spezifische antikörper und methoden zu ihrer verwendung
|
KR101614494B1
(ko)
|
2008-04-02 |
2016-04-22 |
마크로제닉스, 인크. |
Bcr-복합체-특이적 항체 및 그것의 사용 방법
|
EP2161031A1
(de)
|
2008-09-05 |
2010-03-10 |
SuppreMol GmbH |
Fc-gamma-Rezeptor zur Behandlung von B-Zellen-vermittelter multipler Sklerose
|
EP2382238A1
(de)
|
2008-12-31 |
2011-11-02 |
Biogen Idec MA Inc. |
Anti-lymphotoxin-antik?rper
|
JP2012139106A
(ja)
*
|
2009-04-22 |
2012-07-26 |
Uha Mikakuto Co Ltd |
可溶化sr−a蛋白質の製造方法及びそれを用いた評価方法
|
BR112012004094A2
(pt)
|
2009-08-24 |
2016-03-08 |
Amunix Operating Inc |
composições de fator vii de coagulação e métodos para fazer e usar as mesmas
|
ES2672121T3
(es)
|
2009-10-07 |
2018-06-12 |
Macrogenics, Inc. |
Polipéptidos que contienen región Fc que presentan una función efectora mejorada debido a alteraciones del grado de fucosilación, y métodos para su uso
|
SG10201912571XA
(en)
|
2009-11-02 |
2020-02-27 |
Univ Washington |
Therapeutic nuclease compositions and methods
|
WO2011068853A2
(en)
|
2009-12-01 |
2011-06-09 |
Boston Medical Center Corporation |
TREATMENT OF IgE-MEDIATED DISEASE
|
JP5575463B2
(ja)
*
|
2009-12-02 |
2014-08-20 |
東ソー株式会社 |
抗体結合タンパク質およびそれの製造方法
|
LT2542256T
(lt)
|
2010-03-04 |
2019-10-25 |
Macrogenics Inc |
Su b7-h3 reaguojantys antikūnai, jų imunologiškai aktyvūs fragmentai ir jų naudojimas
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
JP5812627B2
(ja)
|
2010-03-10 |
2015-11-17 |
公益財団法人相模中央化学研究所 |
改良Fc受容体およびその製造方法
|
EP2591099B1
(de)
|
2010-07-09 |
2020-11-18 |
Bioverativ Therapeutics Inc. |
Chimäre gerinnungsfaktoren
|
JP2012072091A
(ja)
*
|
2010-09-29 |
2012-04-12 |
Tosoh Corp |
抗体の精製方法
|
EP2492689B8
(de)
*
|
2011-02-22 |
2013-12-25 |
Bernhard-Nocht-Institut für Tropenmedizin |
Nachweis von Antikörpern mit einem verbesserten Immunkomplex- (IC) ELISA
|
NZ616989A
(en)
|
2011-04-29 |
2016-03-31 |
Univ Washington |
Therapeutic nuclease compositions and methods
|
WO2012170969A2
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
CA2840951A1
(en)
*
|
2011-07-08 |
2013-01-17 |
Merck Sharp & Dohme Corp. |
Methods for purifying fc-fusion protein
|
US9738707B2
(en)
|
2011-07-15 |
2017-08-22 |
Biogen Ma Inc. |
Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
|
CA2842559A1
(en)
|
2011-07-20 |
2013-01-24 |
Zepteon, Incorporated |
Polypeptide separation methods
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
CN103890002A
(zh)
*
|
2011-10-19 |
2014-06-25 |
罗切格利卡特公司 |
岩藻糖基化抗体的分离方法
|
JP6483442B2
(ja)
|
2011-12-05 |
2019-03-13 |
エックス−ボディ インコーポレイテッド |
Pdgf受容体ベータ結合ポリペプチド
|
MY201293A
(en)
|
2012-01-12 |
2024-02-15 |
Bioverativ Therapeutics Inc |
Chimeric factor viii polypeptides and uses thereof
|
JP6383666B2
(ja)
|
2012-02-15 |
2018-08-29 |
バイオベラティブ セラピューティクス インコーポレイテッド |
組換え第viii因子タンパク質
|
RS63870B1
(sr)
|
2012-02-15 |
2023-01-31 |
Bioverativ Therapeutics Inc |
Sastavi faktora viii i postupci za pravljenje i upotrebu istih
|
JP2013172655A
(ja)
*
|
2012-02-23 |
2013-09-05 |
Tosoh Corp |
Fc結合性タンパク質およびその製造方法
|
SG11201405162YA
(en)
|
2012-03-28 |
2014-09-26 |
Sanofi Sa |
Antibodies to bradykinin b1 receptor ligands
|
WO2013169657A1
(en)
|
2012-05-07 |
2013-11-14 |
Sanofi |
Methods for preventing biofilm formation
|
WO2013175276A1
(en)
|
2012-05-23 |
2013-11-28 |
Argen-X B.V |
Il-6 binding molecules
|
EP2863940A4
(de)
|
2012-06-08 |
2016-08-10 |
Biogen Ma Inc |
Chimäre gerinnungsfaktoren
|
EP2858659B1
(de)
|
2012-06-08 |
2019-12-25 |
Bioverativ Therapeutics Inc. |
Prokoagulationsverbindungen
|
US10023628B2
(en)
|
2012-07-06 |
2018-07-17 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor VIII polypeptides and uses thereof
|
DK2882450T3
(da)
|
2012-07-11 |
2020-02-24 |
Bioverativ Therapeutics Inc |
Faktor viii-kompleks med xten og von willebrand-faktorprotein samt anvendelser deraf
|
PT2895513T
(pt)
|
2012-09-12 |
2018-10-08 |
Genzyme Corp |
Polipéptidos contendo fc com glicosilação alterada e função efetora reduzida
|
US9790268B2
(en)
|
2012-09-12 |
2017-10-17 |
Genzyme Corporation |
Fc containing polypeptides with altered glycosylation and reduced effector function
|
US10669324B2
(en)
|
2012-10-30 |
2020-06-02 |
Suppremol Gmbh |
Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein
|
US10028998B2
(en)
|
2012-10-30 |
2018-07-24 |
Suppremol Gmbh |
Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
|
WO2014067959A1
(en)
|
2012-10-30 |
2014-05-08 |
Suppremol Gmbh |
A pharmaceutical composition for use in treating or preventing either one or both of an inflammatory disease and an autoimmune disease
|
EP3524691A1
(de)
|
2012-12-07 |
2019-08-14 |
SuppreMol GmbH |
Schichtung und behandlung von patienten von idiopathischer thrombozytopenischer purpura
|
HRP20231183T1
(hr)
|
2013-02-15 |
2024-01-05 |
Bioverativ Therapeutics Inc. |
Optimizirani gen faktora viii
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
IL275376B2
(en)
|
2013-03-11 |
2024-01-01 |
Genzyme Corp |
Polypeptides with hyperglycosidic bonds
|
SG10201707600XA
(en)
|
2013-03-15 |
2017-11-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
EP2796144A1
(de)
|
2013-04-26 |
2014-10-29 |
SuppreMol GmbH |
Hochkonzentrierte Formulierungen von löslichen Fc-Rezeptoren
|
EP2833139A1
(de)
|
2013-08-01 |
2015-02-04 |
SuppreMol GmbH |
In-Vitro-Verfahren zur Bestimmung der Stabilität von Zusammensetzungen enthaltend lösliche FC-Gamma-Rezeptor(en)
|
WO2015021423A2
(en)
|
2013-08-08 |
2015-02-12 |
Biogen Idec Ma Inc. |
Purification of chimeric fviii molecules
|
TWI592426B
(zh)
|
2013-08-13 |
2017-07-21 |
賽諾菲公司 |
胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
|
UA118267C2
(uk)
|
2013-08-13 |
2018-12-26 |
Санофі |
Антитіло до інгібітора активатора плазміногену 1 (раі-1) та його застосування
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
EP2837637A1
(de)
|
2013-08-16 |
2015-02-18 |
SuppreMol GmbH |
Neuartiger FcyRIIB IgG-Antikörper
|
EP3048112B1
(de)
*
|
2013-09-18 |
2020-03-11 |
Tosoh Corporation |
Fc-bindendes protein, verfahren zur herstellung davon und antikörperadsorptionsmittel mit diesem protein und verfahren zur reinigung und identifizierung des antikörpers unter verwendung dieses adsorptionsmittels
|
JP2015083558A
(ja)
*
|
2013-09-18 |
2015-04-30 |
東ソー株式会社 |
抗体吸着剤ならびにそれを用いた抗体の精製方法および識別方法
|
JP6507522B2
(ja)
*
|
2013-09-27 |
2019-05-08 |
東ソー株式会社 |
改良Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤
|
WO2015041303A1
(ja)
*
|
2013-09-18 |
2015-03-26 |
東ソー株式会社 |
Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤、ならびに当該吸着剤を用いた抗体の精製方法および識別方法
|
WO2015048330A2
(en)
|
2013-09-25 |
2015-04-02 |
Biogen Idec Ma Inc. |
On-column viral inactivation methods
|
CA2927263C
(en)
*
|
2013-10-16 |
2022-12-13 |
Suppremol Gmbh |
Soluble fc gamma receptor for treatment of autoimmune bullous diseases
|
US10988745B2
(en)
|
2013-10-31 |
2021-04-27 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-albumin fusions and methods
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
AU2015204646B2
(en)
|
2014-01-10 |
2020-08-27 |
Bioverativ Therapeutics Inc. |
Factor VIII chimeric proteins and uses thereof
|
JP6387640B2
(ja)
*
|
2014-03-19 |
2018-09-12 |
東ソー株式会社 |
Fcレセプターの保存方法
|
CN116333148A
(zh)
|
2014-03-19 |
2023-06-27 |
建新公司 |
靶向模块的位点特异性糖工程化
|
RU2723940C2
(ru)
|
2014-03-21 |
2020-06-18 |
Экс-Боди, Инк. |
Биспецифические антигенсвязывающие полипептиды
|
CN106574261B
(zh)
*
|
2014-06-27 |
2021-02-05 |
东曹株式会社 |
改良Fc结合蛋白、及制造方法、使用该蛋白的抗体吸附剂和使用该吸附剂的抗体分离方法
|
JP6699096B2
(ja)
*
|
2014-06-27 |
2020-05-27 |
東ソー株式会社 |
改良Fc結合性タンパク質、当該タンパク質の製造方法および当該タンパク質を用いた抗体吸着剤
|
WO2015199154A1
(ja)
*
|
2014-06-27 |
2015-12-30 |
東ソー株式会社 |
改良Fc結合性タンパク質、当該タンパク質の製造方法、当該タンパク質を用いた抗体吸着剤および当該吸着剤を用いた抗体の分離方法
|
EP3160478A4
(de)
|
2014-06-30 |
2018-05-16 |
Bioverativ Therapeutics Inc. |
Optimiertes faktor-ix-gen
|
JP2018500272A
(ja)
|
2014-09-26 |
2018-01-11 |
バイエル ファーマ アクチエンゲゼルシャフト |
安定化アドレノメデュリン誘導体およびその使用
|
CA2964123C
(en)
|
2014-10-09 |
2023-09-05 |
Genzyme Corporation |
Glycoengineered antibody drug conjugates
|
CA3203273A1
(en)
|
2014-10-14 |
2016-04-21 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
JP6665414B2
(ja)
*
|
2015-03-25 |
2020-03-13 |
東ソー株式会社 |
Fc結合性タンパク質の保存方法
|
WO2017019729A1
(en)
|
2015-07-27 |
2017-02-02 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
MX2018001497A
(es)
|
2015-08-03 |
2018-05-15 |
Bioverativ Therapeutics Inc |
Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
|
WO2017046746A1
(en)
|
2015-09-15 |
2017-03-23 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
|
EP3192806A1
(de)
|
2016-01-13 |
2017-07-19 |
Affiris AG |
Alpha-kette des hochaffinen ige-rezeptors (fceria)
|
SI3411478T1
(sl)
|
2016-02-01 |
2022-10-28 |
Bioverativ Therapeutics Inc. |
Optimirani geni dejavnika VIII
|
JP6710451B2
(ja)
*
|
2016-03-31 |
2020-06-17 |
東ソー株式会社 |
改変型組換えFcγRIIb
|
MX2018012433A
(es)
|
2016-04-15 |
2019-03-01 |
Macrogenics Inc |
Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.
|
CN109790526A
(zh)
|
2016-07-01 |
2019-05-21 |
分解治疗有限责任公司 |
优化的二核酸酶融合体和方法
|
JP2018050616A
(ja)
|
2016-09-23 |
2018-04-05 |
東ソー株式会社 |
改良型組換えFcγRII
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
BR112019011198A2
(pt)
|
2016-12-02 |
2019-12-17 |
Bioverativ Therapeutics Inc |
métodos de indução de tolerância imune a fatores de coagulação
|
MX2019006444A
(es)
|
2016-12-02 |
2019-10-30 |
Bioverativ Therapeutics Inc |
Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
|
EP3565586A1
(de)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics, Inc. |
Erweiterung von tumorinfiltrierenden lymphozyten mit kaliumkanalagonisten und therapeutische verwendungen davon
|
TW201837168A
(zh)
|
2017-01-06 |
2018-10-16 |
美商艾歐凡斯生物治療公司 |
以腫瘤壞死因子受體超家族(tnfrsf)促效劑使腫瘤浸潤淋巴球(til)擴增及til與tnfrsf促效劑的治療組合
|
CN110832070A
(zh)
|
2017-05-10 |
2020-02-21 |
艾欧凡斯生物治疗公司 |
液体肿瘤来源肿瘤浸润淋巴细胞的扩增及其治疗用途
|
US20210163986A1
(en)
|
2017-08-09 |
2021-06-03 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof
|
WO2019040674A1
(en)
|
2017-08-22 |
2019-02-28 |
Sanabio, Llc |
SOLUBLE INTERFERON RECEPTORS AND USES THEREOF
|
WO2019054782A1
(ko)
*
|
2017-09-15 |
2019-03-21 |
국민대학교 산학협력단 |
Fc 감마 수용체 변이체들
|
WO2019083048A1
(ja)
|
2017-10-27 |
2019-05-02 |
東ソー株式会社 |
アルカリ耐性が向上したFc結合性タンパク質、当該タンパク質の製造方法、当該タンパク質を用いた抗体吸着剤および当該抗体吸着剤を用いて抗体を分離する方法
|
EP3714041A1
(de)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion von peripheren blutlymphozyten (pbls) aus peripherem blut
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
SG11202007114VA
(en)
|
2018-02-01 |
2020-08-28 |
Bioverativ Therapeutics Inc |
Use of lentiviral vectors expressing factor viii
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
MX2020009975A
(es)
|
2018-03-28 |
2020-10-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso.
|
JP2021523878A
(ja)
|
2018-05-18 |
2021-09-09 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病aを処置する方法
|
US20210238289A1
(en)
|
2018-06-04 |
2021-08-05 |
Biogen Ma Inc. |
Anti-vla-4 antibodies having reduced effector function
|
WO2020010117A2
(en)
|
2018-07-03 |
2020-01-09 |
Bristol-Myers Squibb Company |
Fgf21 formulations
|
CA3108799A1
(en)
|
2018-08-09 |
2020-02-13 |
Bioverativ Therapeutics Inc. |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
SG11202106686PA
(en)
|
2019-01-04 |
2021-07-29 |
Resolve Therapeutics Llc |
Treatment of sjogren's disease with nuclease fusion proteins
|
KR20210136050A
(ko)
|
2019-03-01 |
2021-11-16 |
이오반스 바이오테라퓨틱스, 인크. |
액상 종양으로부터의 종양 침윤 림프구의 확장 및 그의 치료 용도
|
AU2020253455A1
(en)
|
2019-04-03 |
2021-11-04 |
Genzyme Corporation |
Anti-alpha beta TCR binding polypeptides with reduced fragmentation
|
JP2022537369A
(ja)
|
2019-06-18 |
2022-08-25 |
バイエル アクチェンゲゼルシャフト |
長期安定化のためのアドレノメデュリン-類似体およびその使用
|
WO2021067389A1
(en)
|
2019-09-30 |
2021-04-08 |
Bioverativ Therapeutics Inc. |
Lentiviral vector formulations
|
US20230087600A1
(en)
|
2020-02-06 |
2023-03-23 |
Bristol-Myers Squibb Company |
Il-10 and uses thereof
|
WO2021174034A1
(en)
|
2020-02-28 |
2021-09-02 |
Genzyme Corporation |
Modified binding polypeptides for optimized drug conjugation
|
US20230355722A1
(en)
|
2020-06-29 |
2023-11-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren’s syndrome with nuclease fusion proteins
|
EP4225330A1
(de)
|
2020-10-06 |
2023-08-16 |
Iovance Biotherapeutics, Inc. |
Behandlung von nsclc-patienten mit tumorinfiltrierenden lymphozytentherapien
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2022125941A1
(en)
|
2020-12-11 |
2022-06-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
JP2023554395A
(ja)
|
2020-12-17 |
2023-12-27 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Ctla-4及びpd-1阻害剤と併用した腫瘍浸潤リンパ球療法による治療
|
CA3202473A1
(en)
|
2020-12-17 |
2022-06-23 |
Friedrich Graf Finckenstein |
Treatment of cancers with tumor infiltrating lymphocytes
|
TW202242085A
(zh)
|
2020-12-31 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
供自動生產腫瘤浸潤淋巴球的裝置和方法
|
EP4284919A1
(de)
|
2021-01-29 |
2023-12-06 |
Iovance Biotherapeutics, Inc. |
Verfahren zur herstellung von modifizierten tumorinfiltrierenden lymphozyten und deren verwendung in der adoptiven zelltherapie
|
WO2022187741A2
(en)
|
2021-03-05 |
2022-09-09 |
Iovance Biotherapeutics, Inc. |
Tumor storage and cell culture compositions
|
TW202304480A
(zh)
|
2021-03-19 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球(til)中之與cd39/cd69選擇及基因剔除相關之til擴增之方法
|
TW202305118A
(zh)
|
2021-03-23 |
2023-02-01 |
美商艾歐凡斯生物治療公司 |
腫瘤浸潤淋巴球之cish基因編輯及其在免疫療法中之用途
|
EP4314253A2
(de)
|
2021-03-25 |
2024-02-07 |
Iovance Biotherapeutics, Inc. |
Verfahren und zusammensetzungen für t-zell-kokulturpotenztests und verwendung mit zelltherapieprodukten
|
WO2022225981A2
(en)
|
2021-04-19 |
2022-10-27 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
EP4340850A1
(de)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1-geneditierte tumorinfiltrierende lymphozyten und verwendungen davon in der immuntherapie
|
WO2023004074A2
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
IL311333A
(en)
|
2021-09-09 |
2024-05-01 |
Iovance Biotherapeutics Inc |
Processes for the production of TIL products using a strong PD-1 TALEN
|
WO2023049862A1
(en)
|
2021-09-24 |
2023-03-30 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
TW202331735A
(zh)
|
2021-10-27 |
2023-08-01 |
美商艾歐凡斯生物治療公司 |
協調用於患者特異性免疫療法之細胞之製造的系統及方法
|
AU2022388729A1
(en)
|
2021-11-10 |
2024-05-16 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
US20240101691A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
US20240166750A1
(en)
|
2022-10-25 |
2024-05-23 |
Ablynx N.V. |
GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|